Sachidananda Behera
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sachidananda Behera has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Vikash Kumar Nayak
Central University of Kerala, India
3 shared publications - Ashutosh Kumar Maurya
Central University of Kerala, India
1 shared publication - Ashutosh Kumar Maurya
Independent Researcher, India
1 shared publication - Swayamprava Satapathy
Pondicherry University, India
1 shared publication - V. B. Sameer Kumar
Central University of Kerala, India
1 shared publication
Latest Publications
- Open Access
- 22 April 2026
- Published by MDPI AG in Preprints.org
The World’s Five Deadliest Cancers: Current Trends, Therapeutics, and Future Directions
Cancer remains a leading cause of death worldwide, with breast, lung, colorectal, prostate, and cervical cancers contributing significantly to global cancer-related morbidity and mortality. While individual lethality varies among these cancers, their combined impact on public health is substantial due to high incidence and, in some cases, limited access to early detection and effective treatment. These malignancies arise from a complex interplay of genetic, hormonal, lifestyle, and infectious factors, with molecular mechanisms that inform targeted therapies and precision medicine approaches. Advances in screening, immunotherapy, AI-assisted diagnostics, and minimally invasive surgical techniques have improved outcomes; however, challenges such as late diagnosis, treatment resistance, and healthcare disparities persist, particularly in low- and middle-income countries. This review provides a comprehensive synthesis of the epidemiology, risk factors, molecular pathogenesis, clinical features, current treatment strategies, emerging technologies, public health implications, and future research directions for the five deadliest cancers. Emphasis is placed on preventive measures, early detection, and equitable access to care, highlighting strategies to reduce the global cancer burden and improve survival outcomes.
- 22 April 2026
- Published by MDPI AG in Preprints.org
Open AccessThe World’s Five Deadliest Cancers: Current Trends, Therapeutics, and Future Directions
Cancer remains a leading cause of death worldwide, with breast, lung, colorectal, prostate, and cervical cancers contributing significantly to global cancer-related morbidity and mortality. While individual lethality varies among these cancers, their combined impact on public health is substantial due to high incidence and, in some cases, limited access to early detection and effective treatment. These malignancies arise from a complex interplay of genetic, hormonal, lifestyle, and infectious factors, with molecular mechanisms that inform targeted therapies and precision medicine approaches. Advances in screening, immunotherapy, AI-assisted diagnostics, and minimally invasive surgical techniques have improved outcomes; however, challenges such as late diagnosis, treatment resistance, and healthcare disparities persist, particularly in low- and middle-income countries. This review provides a comprehensive synthesis of the epidemiology, risk factors, molecular pathogenesis, clinical features, current treatment strategies, emerging technologies, public health implications, and future research directions for the five deadliest cancers. Emphasis is placed on preventive measures, early detection, and equitable access to care, highlighting strategies to reduce the global cancer burden and improve survival outcomes.
- Open Access
- 21 April 2026
- Published by MDPI AG in Preprints.org
From Editing Genes to Orchestrating Networks: CRISPR and the Future of Precision Oncology
The advent of CRISPR-based genome editing has transformed the conceptual framework of oncology—from descriptive molecular profiling to functional genome engineering. By enabling precise, programmable, and multiplex control of cancer-associated genes, CRISPR/Cas systems are reshaping how we model tumorigenesis, predict drug response, and design patient-tailored interventions. This Perspective discusses how CRISPR technologies are redefining precision oncology, the biological and ethical challenges that impede their clinical translation, and emerging strategies that integrate gene editing with immunotherapy, synthetic biology, and systems medicine. We argue that the future of cancer therapy lies not merely in editing genes but in orchestrating the dynamic networks that sustain malignancy.
- 21 April 2026
- Published by MDPI AG in Preprints.org
Open AccessFrom Editing Genes to Orchestrating Networks: CRISPR and the Future of Precision Oncology
The advent of CRISPR-based genome editing has transformed the conceptual framework of oncology—from descriptive molecular profiling to functional genome engineering. By enabling precise, programmable, and multiplex control of cancer-associated genes, CRISPR/Cas systems are reshaping how we model tumorigenesis, predict drug response, and design patient-tailored interventions. This Perspective discusses how CRISPR technologies are redefining precision oncology, the biological and ethical challenges that impede their clinical translation, and emerging strategies that integrate gene editing with immunotherapy, synthetic biology, and systems medicine. We argue that the future of cancer therapy lies not merely in editing genes but in orchestrating the dynamic networks that sustain malignancy.
- Open Access
- 21 April 2026
- Published by MDPI AG in Preprints.org
Oncology Meets Virology: Exploring Viral Contributions to Cancer Development and Therapy
Viruses contribute to a substantial fraction of human cancers globally, with an estimated 12–15% of all cancer cases being linked to viral infections. This review synthesizes the current understanding of oncogenic viruses, their mechanisms of viral carcinogenesis, and the types of cancers associated with different viral pathogens. We explore the evolving therapeutic landscape, including vaccines, immunotherapies, and oncolytic virotherapy, and discuss the latest advances in clinical trials. The review also examines the challenges of viral cancer treatment, such as immune evasion and resistance to therapies, and looks forward to promising future directions in personalised medicine, advanced viral therapies, and drug discovery. The intersection of virology and oncology offers new opportunities for cancer prevention and treatment that could transform patient outcomes globally.
- 21 April 2026
- Published by MDPI AG in Preprints.org
Open AccessOncology Meets Virology: Exploring Viral Contributions to Cancer Development and Therapy
Viruses contribute to a substantial fraction of human cancers globally, with an estimated 12–15% of all cancer cases being linked to viral infections. This review synthesizes the current understanding of oncogenic viruses, their mechanisms of viral carcinogenesis, and the types of cancers associated with different viral pathogens. We explore the evolving therapeutic landscape, including vaccines, immunotherapies, and oncolytic virotherapy, and discuss the latest advances in clinical trials. The review also examines the challenges of viral cancer treatment, such as immune evasion and resistance to therapies, and looks forward to promising future directions in personalised medicine, advanced viral therapies, and drug discovery. The intersection of virology and oncology offers new opportunities for cancer prevention and treatment that could transform patient outcomes globally.